Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that its 2020 Annual Meeting of Stockholders (including any adjournments or postponements, the “Annual Meeting”) has been changed to a virtual-only format. This decision reflects public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and governmental restrictions limiting the number of people who may gather together, and is intended to support the health and well-being of Kala’s stockholders, employees and communities.

As previously announced, the Annual Meeting will be held at 9:00 a.m. Eastern Time, on Thursday, June 25, 2020. Stockholders will not be able to attend the Annual Meeting in person, but instead will be able to attend virtually. Stockholders will be able to participate in the Annual Meeting, vote shares electronically and submit questions during the live audio webcast of the Annual Meeting by visiting www.virtualshareholdermeeting.com/KALA2020 and entering the 16-digit control number found on the proxy card, voting instruction form or notice previously distributed.

As described in the proxy materials for the Annual Meeting that were previously distributed, stockholders are entitled to participate in and vote at the Annual Meeting if they were a stockholder of Kala as of the close of business on April 27, 2020, the record date.

Whether or not a stockholder plans to participate in the live audio webcast of the Annual Meeting, Kala urges all stockholders to vote and submit their proxies in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting that were previously provided to the stockholders. The proxy card included with these proxy materials will not be updated to reflect the change in location and may continue to be used to vote stockholder shares in connection with the Annual Meeting.

A notice regarding this change to a virtual meeting format, additional information regarding the virtual Annual Meeting and this press release are included in a proxy supplement that Kala has filed today with the Securities and Exchange Commission.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFYTM mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, for which a New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) with a target action date under the Prescription Drug User Fee Act (PDUFA) set for October 30, 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005023/en/